PL366459A1 - Nowe związki pirydylocyjanoguanidyny - Google Patents
Nowe związki pirydylocyjanoguanidynyInfo
- Publication number
- PL366459A1 PL366459A1 PL02366459A PL36645902A PL366459A1 PL 366459 A1 PL366459 A1 PL 366459A1 PL 02366459 A PL02366459 A PL 02366459A PL 36645902 A PL36645902 A PL 36645902A PL 366459 A1 PL366459 A1 PL 366459A1
- Authority
- PL
- Poland
- Prior art keywords
- halogen
- alkylcarbonyl
- aminoalkyl
- formyl
- alkoxycarbonyl
- Prior art date
Links
- CPFPCHSTLBKFPH-UHFFFAOYSA-N 1-cyano-1-pyridin-2-ylguanidine Chemical class NC(=N)N(C#N)C1=CC=CC=N1 CPFPCHSTLBKFPH-UHFFFAOYSA-N 0.000 title 1
- -1 nitro, carboxy Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 239000004215 Carbon black (E152) Substances 0.000 abstract 3
- 229930195733 hydrocarbon Natural products 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29292701P | 2001-05-24 | 2001-05-24 | |
| US29292801P | 2001-05-24 | 2001-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366459A1 true PL366459A1 (pl) | 2005-02-07 |
Family
ID=26967641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02366459A PL366459A1 (pl) | 2001-05-24 | 2002-05-24 | Nowe związki pirydylocyjanoguanidyny |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7304066B2 (pl) |
| EP (1) | EP1397355B1 (pl) |
| JP (1) | JP4429607B2 (pl) |
| KR (1) | KR20030097897A (pl) |
| CN (1) | CN1247570C (pl) |
| AT (1) | ATE442362T1 (pl) |
| BR (1) | BR0209930A (pl) |
| CA (1) | CA2447021C (pl) |
| CZ (1) | CZ20033190A3 (pl) |
| DE (1) | DE60233656D1 (pl) |
| ES (1) | ES2328799T3 (pl) |
| HU (1) | HUP0400021A3 (pl) |
| IL (1) | IL158574A0 (pl) |
| MX (1) | MXPA03010669A (pl) |
| PL (1) | PL366459A1 (pl) |
| RU (1) | RU2292344C2 (pl) |
| WO (1) | WO2002094813A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
| EP1713780B1 (en) * | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| WO2006066584A1 (en) * | 2004-12-22 | 2006-06-29 | Leo Pharma A/S | Novel cyanoguanidine compounds |
| AR055343A1 (es) | 2005-06-30 | 2007-08-22 | Smithkline Beecham Corp | Derivados de indolcarboxamida inhibidores de quinasas ikk2 |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| US8871747B2 (en) | 2008-08-29 | 2014-10-28 | Topotarget A/S | Urea and thiourea derivatives |
| CA2751495C (en) * | 2009-02-06 | 2013-08-20 | Tianjin Hemay Bio-Tech Co., Ltd. | Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| WO2011006988A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| US8604065B2 (en) | 2010-02-04 | 2013-12-10 | Hesheng Zhang | Pyridyl cyanoguanidine derivatives |
| WO2011095027A1 (zh) * | 2010-02-04 | 2011-08-11 | 天津和美生物技术有限公司 | 吡啶基氰基胍衍生物 |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| TW201216963A (en) * | 2010-09-03 | 2012-05-01 | Forma Therapeutics Inc | Novel compounds and compositions for the inhibition of NAMPT |
| JP2013540781A (ja) | 2010-10-26 | 2013-11-07 | ティエンジン ホーメイ バイオ−テック カンパニー， リミテッド | Ｎ−（６−（４−クロロフェノキシ）ヘキシル）−ｎ’−シアノ−ｎ’’−（４−ピリジル）グアニジンの結晶多形とその製造及び使用 |
| HUE029466T2 (en) * | 2010-12-09 | 2017-02-28 | Radikal Therapeutics Inc | Multifunctional nitroxide derivatives and their use |
| MX367793B (es) * | 2012-04-13 | 2019-09-06 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| KR101656663B1 (ko) | 2015-07-27 | 2016-09-13 | 충남대학교산학협력단 | 암 예방 및 치료용 조성물 |
| HUE061963T2 (hu) | 2018-08-17 | 2023-09-28 | Novartis Ag | Karbamid-vegyületek és készítmények mint SMARCA2/BRM-ATPáz gátlók |
| CN110734405A (zh) * | 2019-11-11 | 2020-01-31 | 华东数字医学工程研究院 | 一种n-(6-氨己基)-n’-甲基-2,2’-联咪唑的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219472D0 (en) | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| US5696140A (en) * | 1992-09-15 | 1997-12-09 | Leo Pharmaceutical Products Ltd. | N-cyano-N'-pyridylguanidines as serotonin antagonists |
| GB9711119D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711122D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| US7129043B1 (en) * | 1998-10-22 | 2006-10-31 | Duke University | Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease |
| AU4076500A (en) * | 1999-04-09 | 2000-11-14 | Shionogi Bioresearch Corp. | (n)-substituted cyanoguanidine compounds |
| AU4080300A (en) | 1999-04-09 | 2000-11-14 | Shionogi Bioresearch Corp. | Cyanoguanidine compounds |
| US6645968B2 (en) | 1999-08-03 | 2003-11-11 | Abbott Laboratories | Potassium channel openers |
| CA2378936A1 (en) | 1999-08-03 | 2001-02-08 | Abbott Laboratories | Potassium channel openers |
-
2002
- 2002-05-24 WO PCT/DK2002/000353 patent/WO2002094813A1/en not_active Ceased
- 2002-05-24 PL PL02366459A patent/PL366459A1/pl not_active Application Discontinuation
- 2002-05-24 KR KR10-2003-7015244A patent/KR20030097897A/ko not_active Ceased
- 2002-05-24 CN CNB028101022A patent/CN1247570C/zh not_active Expired - Lifetime
- 2002-05-24 US US10/476,856 patent/US7304066B2/en not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010669A patent/MXPA03010669A/es not_active Application Discontinuation
- 2002-05-24 AT AT02771630T patent/ATE442362T1/de not_active IP Right Cessation
- 2002-05-24 BR BR0209930-6A patent/BR0209930A/pt not_active IP Right Cessation
- 2002-05-24 CZ CZ20033190A patent/CZ20033190A3/cs unknown
- 2002-05-24 ES ES02771630T patent/ES2328799T3/es not_active Expired - Lifetime
- 2002-05-24 JP JP2002591486A patent/JP4429607B2/ja not_active Expired - Fee Related
- 2002-05-24 CA CA2447021A patent/CA2447021C/en not_active Expired - Lifetime
- 2002-05-24 HU HU0400021A patent/HUP0400021A3/hu unknown
- 2002-05-24 DE DE60233656T patent/DE60233656D1/de not_active Expired - Lifetime
- 2002-05-24 IL IL15857402A patent/IL158574A0/xx unknown
- 2002-05-24 EP EP02771630A patent/EP1397355B1/en not_active Expired - Lifetime
- 2002-05-24 RU RU2003137007/04A patent/RU2292344C2/ru active
-
2007
- 2007-11-30 US US11/998,575 patent/US7807682B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL158574A0 (en) | 2004-05-12 |
| EP1397355A1 (en) | 2004-03-17 |
| DE60233656D1 (de) | 2009-10-22 |
| US7807682B2 (en) | 2010-10-05 |
| CN1247570C (zh) | 2006-03-29 |
| KR20030097897A (ko) | 2003-12-31 |
| US20080090842A1 (en) | 2008-04-17 |
| EP1397355B1 (en) | 2009-09-09 |
| HUP0400021A3 (en) | 2008-03-28 |
| CA2447021C (en) | 2010-08-10 |
| CA2447021A1 (en) | 2002-11-28 |
| JP4429607B2 (ja) | 2010-03-10 |
| MXPA03010669A (es) | 2004-07-01 |
| ES2328799T3 (es) | 2009-11-18 |
| JP2005508859A (ja) | 2005-04-07 |
| HK1066216A1 (en) | 2005-03-18 |
| US7304066B2 (en) | 2007-12-04 |
| HUP0400021A2 (hu) | 2004-04-28 |
| CN1509283A (zh) | 2004-06-30 |
| RU2292344C2 (ru) | 2007-01-27 |
| ATE442362T1 (de) | 2009-09-15 |
| WO2002094813A1 (en) | 2002-11-28 |
| US20040220408A1 (en) | 2004-11-04 |
| RU2003137007A (ru) | 2005-04-20 |
| BR0209930A (pt) | 2004-03-30 |
| CZ20033190A3 (cs) | 2004-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL158574A0 (en) | Novel pyridyl cyanoguanidine compounds | |
| AU2002246728A1 (en) | Carboline derivatives | |
| MY135841A (en) | Novel benzodioxoles | |
| UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| MXPA05013142A (es) | Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. | |
| PL377285A1 (pl) | Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy | |
| BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
| GB2369360A (en) | 5-cyano-2-aminopyrimidine derivatives | |
| BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
| IL189694A0 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
| IL164511A0 (en) | Heterocyclic compounds | |
| MXPA03007621A (es) | Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos. | |
| MY130697A (en) | 4-trifluoromethylpyrazolyl-substituted pyridines and pyrimidines | |
| MY144622A (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| AU2002249890A1 (en) | Carboline derivatives | |
| MY138737A (en) | N3-substituted imidazopyridine c-kit inhibitors | |
| AU2002213421A1 (en) | Condensed pyridoindole derivatives | |
| TW200508199A (en) | Novel compound | |
| AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| MXPA03002909A (es) | Compuestos quimicos. | |
| IL161842A0 (en) | 2-Amino-4-heteroarylethyl-thiazoline derivatives and their use as inhibitors of inducible no-synthase | |
| MXPA03003971A (es) | Derivados de indol como inhibidores de pde5. | |
| AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
| MXPA03000887A (es) | Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |